Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

PURPOSE: When during cancer treatment resistance to a tyrosine kinase inhibitor (TKI) occurs, switching to another TKI is often considered as a reasonable option. Previously, we reported that resistance to sunitinib may be caused by increased lysosomal sequestration, leading to increased intracellul...

Descripción completa

Detalles Bibliográficos
Autores principales: Gotink, Kristy J., Rovithi, Maria, de Haas, Richard R., Honeywell, Richard J., Dekker, Henk, Poel, Dennis, Azijli, Kaamar, Peters, Godefridus J., Broxterman, Henk J., Verheul, Henk M. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2015
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555235/
https://www.ncbi.nlm.nih.gov/pubmed/25665527
http://dx.doi.org/10.1007/s13402-015-0218-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555235/
https://www.ncbi.nlm.nih.gov/pubmed/25665527
http://dx.doi.org/10.1007/s13402-015-0218-8

Ejemplares similares